suppression

(redirected from Myelosuppression)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
References in periodicals archive ?
In that study, among the patients who received more than 10 days of drug therapy, one-third of patients in linezolid group experienced a platelet reduction of at least 30 percent by the end of therapy, with no such myelosuppression detected in 800 mg MRX-I group.
Side-effects include skin rash, myelosuppression, neurotoxicity, fatigue, nausea, vomiting, diarrhoea and myalgia and arthralgia.
decreased number of platelets) are types of myelosuppression.
Serious: myelosuppression (neutropenia and thrombocytopenia), toxic epidermal necrolysis and Stevens-Johnson syndrome, hallucination, amnesia, status epilepticus, cerebral haemorrhage, embolism pulmonary, pancytopenia, anaemia (grade 3-4), leukopenia.
Thus, if there is an unexpected or prolonged myelosuppression in oncology patients presenting with fever and DIC findings, HPS should be included in the differential diagnosis.
drug related toxicities, including myelosuppression and alopecia, in any of the
The company believes that this individual assessment of patient acetylator status will maximize antitumor response while minimizing adverse outcomes from excessive myelosuppression.
Many of the side effects of postoperative adjunctive chemotherapy for breast cancer are well established: myelosuppression, hair loss, nausea and vomiting, fatigue, and early menopause.
Significant achievements in clinical practice over the last decade and the launches of efficacious, premium-priced agents drive market expansion, but untapped market potential remains for agents that can improve survival and reduce peripheral neuropathy and/or myelosuppression compared with currently available agents.
Cytotoxic agents that target tubulin remain the most effective agents against advanced prostate cancer, but currently they can only be administered IV and have significant side effects like neurotoxiticity and myelosuppression.
Side effects include myelosuppression, edema, gastrointestinal symptoms, headache, and rash.
Patients treated with TEMODAR Capsules may experience myelosuppression.